001     283198
005     20240229155050.0
024 7 _ |a 10.3390/biomedicines11092348
|2 doi
024 7 _ |a pmid:37760790
|2 pmid
037 _ _ |a DKFZ-2023-01963
041 _ _ |a English
082 _ _ |a 570
100 1 _ |a von Knebel Doeberitz, Nikolaus
|0 P:(DE-He78)857bbcdb8f5f582e00795df8b957767d
|b 0
|e First author
|u dkfz
245 _ _ |a Post-Surgical Depositions of Blood Products Are No Major Confounder for the Diagnostic and Prognostic Performance of CEST MRI in Patients with Glioma.
260 _ _ |a Basel
|c 2023
|b MDPI
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1695986928_24400
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #EA:E010#LA:E010#
520 _ _ |a Amide proton transfer (APT) and semi-solid magnetization transfer (ssMT) imaging can predict clinical outcomes in patients with glioma. However, the treatment of brain tumors is accompanied by the deposition of blood products within the tumor area in most cases. For this reason, the objective was to assess whether the diagnostic interpretation of the APT and ssMT is affected by methemoglobin (mHb) and hemosiderin (Hs) depositions at the first follow-up MRI 4 to 6 weeks after the completion of radiotherapy. A total of 34 participants underwent APT and ssMT imaging by applying reconstruction methods described by Zhou et al. (APTwasym), Goerke et al. (MTRRexAPT and MTRRexMT) and Mehrabian et al. (MTconst). Contrast-enhancing tumor (CE), whole tumor (WT), mHb and Hs were segmented on contrast-enhanced T1wCE, T2w-FLAIR, T1w and T2*w images. ROC-analysis, Kaplan-Meier analysis and the log rank test were used to test for the association of mean contrast values with therapy response and overall survival (OS) before (WT and CE) and after correcting tumor volumes for mHb and Hs (CEC and WTC). CEC showed higher associations of the MTRRexMT with therapy response (CE: AUC = 0.677, p = 0.081; CEC: AUC = 0.705, p = 0.044) and of the APTwasym with OS (CE: HR = 2.634, p = 0.040; CEC: HR = 2.240, p = 0.095). In contrast, WTC showed a lower association of the APTwasym with survival (WT: HR = 2.304, p = 0.0849; WTC: HR = 2.990, p = 0.020). Overall, a sophisticated correction for blood products did not substantially influence the clinical performance of APT and ssMT imaging in patients with glioma early after radiotherapy.
536 _ _ |a 315 - Bildgebung und Radioonkologie (POF4-315)
|0 G:(DE-HGF)POF4-315
|c POF4-315
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a amide proton transfer
|2 Other
650 _ 7 |a blood
|2 Other
650 _ 7 |a chemical exchange saturation transfer MRI
|2 Other
650 _ 7 |a correction
|2 Other
650 _ 7 |a glioma
|2 Other
650 _ 7 |a hemosiderin
|2 Other
650 _ 7 |a methemoglobin
|2 Other
650 _ 7 |a overall survival
|2 Other
650 _ 7 |a radiotherapy
|2 Other
650 _ 7 |a semi-solid magnetization transfer
|2 Other
650 _ 7 |a therapy response
|2 Other
700 1 _ |a Kroh, Florian
|0 P:(DE-He78)a803bc5fee5b7b2093f0fe6074f3d2ea
|b 1
|u dkfz
700 1 _ |a König, Laila
|b 2
700 1 _ |a Boyd, Philip S
|0 P:(DE-He78)3c51ec0b06b6c9ccece5c7b5306de106
|b 3
|u dkfz
700 1 _ |a Graß, Svenja
|0 P:(DE-He78)5530f7eeaa1168b3dc8db60db8853490
|b 4
|u dkfz
700 1 _ |a Bauspieß, Cora
|0 P:(DE-He78)6205350c30f0f6e6364841823c83165a
|b 5
|u dkfz
700 1 _ |a Scherer, Moritz
|0 0000-0003-1203-9351
|b 6
700 1 _ |a Unterberg, Andreas
|b 7
700 1 _ |a Bendszus, Martin
|b 8
700 1 _ |a Wick, Wolfgang
|b 9
700 1 _ |a Bachert, Peter
|0 P:(DE-He78)29b2f01310f7022916255ddba2750f9b
|b 10
|u dkfz
700 1 _ |a Debus, Jürgen
|0 P:(DE-He78)8714da4e45acfa36ce87c291443a9218
|b 11
|u dkfz
700 1 _ |a Ladd, Mark
|0 P:(DE-He78)022611a2317e4de40fd912e0a72293a8
|b 12
|u dkfz
700 1 _ |a Schlemmer, Heinz-Peter
|0 P:(DE-He78)3d04c8fee58c9ab71f62ff80d06b6fec
|b 13
|u dkfz
700 1 _ |a Goerke, Steffen
|0 P:(DE-HGF)0
|b 14
700 1 _ |a Korzowski, Andreas
|0 P:(DE-He78)577a5c61f44b8023e229610afbc7cd4e
|b 15
|u dkfz
700 1 _ |a Paech, Daniel
|0 P:(DE-He78)c6e31fb8f19e185e254174554a0cccfc
|b 16
|e Last author
|u dkfz
773 _ _ |a 10.3390/biomedicines11092348
|g Vol. 11, no. 9, p. 2348 -
|0 PERI:(DE-600)2720867-9
|n 9
|p 2348
|t Biomedicines
|v 11
|y 2023
|x 2227-9059
909 C O |o oai:inrepo02.dkfz.de:283198
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)857bbcdb8f5f582e00795df8b957767d
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)a803bc5fee5b7b2093f0fe6074f3d2ea
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-He78)3c51ec0b06b6c9ccece5c7b5306de106
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 P:(DE-He78)5530f7eeaa1168b3dc8db60db8853490
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 5
|6 P:(DE-He78)6205350c30f0f6e6364841823c83165a
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 10
|6 P:(DE-He78)29b2f01310f7022916255ddba2750f9b
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 11
|6 P:(DE-He78)8714da4e45acfa36ce87c291443a9218
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 12
|6 P:(DE-He78)022611a2317e4de40fd912e0a72293a8
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 13
|6 P:(DE-He78)3d04c8fee58c9ab71f62ff80d06b6fec
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 14
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 15
|6 P:(DE-He78)577a5c61f44b8023e229610afbc7cd4e
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 16
|6 P:(DE-He78)c6e31fb8f19e185e254174554a0cccfc
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-315
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Bildgebung und Radioonkologie
|x 0
914 1 _ |y 2023
915 _ _ |a Creative Commons Attribution CC BY (No Version)
|0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|b DOAJ
|d 2022-01-07T14:28:55Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2023-03-30
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-03-30
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-03-30
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2023-03-30
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2023-03-30
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b BIOMEDICINES : 2022
|d 2023-08-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-08-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-08-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2023-08-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2023-07-07T16:28:21Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2023-07-07T16:28:21Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2023-07-07T16:28:21Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-08-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2023-08-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-08-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2023-08-29
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2023-08-29
920 2 _ |0 I:(DE-He78)E010-20160331
|k E010
|l E010 Radiologie
|x 0
920 1 _ |0 I:(DE-He78)E010-20160331
|k E010
|l E010 Radiologie
|x 0
920 1 _ |0 I:(DE-He78)E020-20160331
|k E020
|l E020 Med. Physik in der Radiologie
|x 1
920 1 _ |0 I:(DE-He78)E050-20160331
|k E050
|l E050 KKE Strahlentherapie
|x 2
920 0 _ |0 I:(DE-He78)E010-20160331
|k E010
|l E010 Radiologie
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)E010-20160331
980 _ _ |a I:(DE-He78)E020-20160331
980 _ _ |a I:(DE-He78)E050-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21